Back in 2005 (and revisited in 2009), the Department of Health and Human Services made an offer. They would provide funds to businesses that could produce a recombinant influenza vaccine, build a manufacturing plant within the contiguous United States, meet a surge capacity of 50 million doses in six months and have vaccine lot releases within 12 weeks of a pandemic declaration. Well, four years later, they’ve done just that! 1
What does this mean for us? It means that the 2013-2014 influenza season will have some new vaccines available to choose from and a whole new nomenclature for us to learn.2
It all started when FluMist3 added a second B-strain to their live attenuated influenza vaccine making the first quadrivalent influenza vaccine for the U.S., LAIV-4.
There won’t be any LAIV-3.
Say good-by to TIV.
The previous TIV family of vaccines is now Inactivated Influenza Vaccine (IIV). There will be a mix of trivalent and quadrivalent injectable influenza vaccines available; IIV-3 and IIV-4.
Not only have we added a second B-strain but we have added the first two non-chicken based vaccines: recombinant influenza vaccine RIV-3 and the first non-chicken cell culture vaccine: ccIIV-3
What does this mean for right now? Unless your vaccine buyer made purchases last fall for these new formulations you may well only carry IIV-3. Just keep in mind that these and others may be available later this year and available for ordering for the 2014-2015 season.
See the table for the 2013-2014 season here.
• There are seven (7) IIV-3 regular vaccines from chicken eggs.
• There is one (1) RIV-3 recombinant vaccine and
• There is one (1) ccIIV-3 cell culture vaccine.
• There are (2) IIV-4 vaccines from chicken eggs. [Fluzone IIV-4 was just approved4.]
• Keep in mind that influenza vaccine is recommended for all individuals’ ≥6 months of age with at least 17 different presentations from which to choose.
1. Donabedian, A. 2012, United States Department of Health and Human Services. Prospects for sustainable influenza pandemic preparedness.
2. Interim Recommendations: Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunizations Practices, (ACIP) 2013.
3. Vaccines, Blood & Biologicals. February 29, 2012 approval letter – FluMist®Qudarivalent.
4. Vaccines, Blood & Biologicals. June 7, 2013 approval letter – Fluzone Quadrivalent.
IMMIE NEWS YOU CAN USE: